Role of pharmacologic rehabilitation in the recovery of sexual function following radical prostatectomy

Minerva Urol Nefrol. 2005 Dec;57(4):325-9.

Abstract

Aim: The aim of the present study is to evaluate the role of pharmacological postoperative sexual rehabilitation in the recovery of erectile function following radical retropubic prostatectomy.

Methods: Following radical retropubic prostatectomy 113 patients were divided into 2 groups: 77 (group 1) underwent pharmacologic rehabilitation with intracavernous PGE1 starting with 5 mg once or twice weekly beginning 1 month after surgery, followed by oral sildenafil 50-100 mg twice a week after recovery of spontaneous erections, while 36 (group 2) acted as controls. The 2 groups were homogeneous for age and preoperative IIEF5 score, while nerve-sparing techniques were used more frequently in group 1.

Results: With 1 year follow-up 42% of group 1 patients have recovered sexual function, versus 8% of group 2 (P < 0.001). The mean recovery time was 7 months, and 56% of rehabilitated patients with bilateral preservation of the neurovascular bundles recovered sexual function, compared to 37.5% of those with unilateral preservation and 28.5% of those operated with non nerve-sparing technique. Intracavernous PGE1 caused pain in 27% of cases.

Conclusions: Pharmacologic rehabilitation significantly impacts on the recovery of sexual function following radical prostatectomy, and the optimal treatment schedule is still to be defined.

MeSH terms

  • Aged
  • Alprostadil / therapeutic use*
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / etiology
  • Erectile Dysfunction / rehabilitation*
  • Humans
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Prostatectomy* / adverse effects
  • Purines
  • Recovery of Function
  • Sildenafil Citrate
  • Sulfones
  • Vasodilator Agents / therapeutic use*

Substances

  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate
  • Alprostadil